SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Celgene

207

Celgene

CELG

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multiple myeloma, inflammatory diseases, and various forms of cancer.

Looking for leads, investment insights, or competitive intelligence?

CEO

Mark J. Alles

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Summit, N.J.

Years on Fortune 500 List

8

Employees

8,852

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$15,28117.5%
Profits ($M)$4,046.037.6%
Assets ($M)$35,480
Total Stockholder Equity ($M)$6,161
Profit Ratios
Profit as % of Revenues26.5%
Profits as % of Assets11.4%
Profits as % of Stockholder Equity65.7%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)5.51
EPS % Change (from 2017)51.4%
EPS % Change (5 year annual rate)26.7%
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2018)-38.6%
Total Return to Investors (5 year, annualized)-5.4%
Total Return to Investors (10 year, annualized)8.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Celgene

Celgene Boosted Price of Top Cancer Drug on Day of Mega-Deal

Celgene boosted the price of a 10-milligram dose of Revlimid by 3.5% to $719.82 effective Jan. 3.

Read More →
The Best Investing Advice for 2019 From Fortune’s Experts

The economy and the stock market don’t always march in lockstep, and investors got a sharp reminder of that fact this fall. Parade-and-fireworks-worthy GDP growth and employment numbers shared the spotlight with an ugly market slide that took some previously beloved stocks into bear-market territory. Fears about inflation and trade tensions were among the culprits; […]

Read More →
Russian Drugmaker Granted License to Produce Celgene Copycat

Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.

Read More →